Newamsterdam Pharma Co. NV-27NAMSWPreferred / convertible
13F holders, Q4 2024 (December 31)11holders
2new positions
2sold out
$14.20avg. 13F price*
At the end of Q4 2024, 11 institutions reported holding Newamsterdam Pharma Co. NV-27 (NAMSW) in their 13F filings, unchanged from Q3 2024. 2 opened new positions and 2 sold out. The largest holders were Frazier Life Sciences Management, L.P. ($7.1M), Ra Capital Management, L.P. ($4.7M) and Affinity Asset Advisors, LLC ($3.3M).
- Company
- Newamsterdam Pharma Co. NV-27
- CUSIP
- N62509117
- Latest filing quarter
- Q2 2026
History
Number of 13F holders
Total Exit/New Position Q3 2024 → Q4 2024
| Institutions | Total Value | |
|---|---|---|
| New Positions | 2 | $216K |
| Exits | 2 | $262K |
All 13F filers, Q3 2024 → Q4 2024: 40,135 shares bought and 50,835 shares sold, net −10,700 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 11 holders
| Frazier Life Sciences Management, L.P. | — | No change | 500,333 | $7.1M |
| Ra Capital Management, L.P. | — | No change | 333,333 | $4.7M |
| Affinity Asset Advisors, LLC | — | Add +11.7% | 237,935 | $3.3M |
| Bain Capital Life Sciences Investors, LLC | — | No change | 100,000 | $1.4M |
| Deerfield Management Company, L.P. | — | No change | 92,787 | $1.3M |
| Laurion Capital Management LP | — | No change | 16,666 | $237K |
| HRT Financial LP | — | Reduce -49.6% | 13,655 | $191K |
| Wolverine Asset Management LLC | — | New | 12,693 | $181K |
| Vestcor Inc | — | No change | 9,632 | $137K |
| UBS Group AG | — | New | 2,481 | $35K |
| CIBC Private Wealth Group LLC | — | No change | 1,000 | $14K |
"% of holder's portfolio" is NAMSW's weight in each manager's 13F, not the share of Newamsterdam Pharma Co. NV-27 the manager owns.